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Clinical Analysis of Hemodialysis Vascular Access: Comparision of 
Autogenous Arterioveonus Fistula & Arteriovenous Prosthetic Graft
Duk-Sil  Kim,  M.D.*,  Sung-Wan  Kim,  M.D.*,  Jun-Chul  Kim,  M.D.**,  Ji-Hyung  Cho,  M.D.**, 
Joon-Hyuk  Kong,  M.D.***,  Chang-Ryul  Park,  M.D.****
Background:  Mature autogenous arteriovenous fistulas have better long term patency and require fewer secondary 
interventions compared to arteriovenous prosthetic graft. Our Study evaluated vascular patency rates and incidence 
of interventions in autogenous arteriovenous fistulas and grafts. Material and Methods: A total of 166 vascular ac-
cess operations were performed in 153 patients between December 2002 and November 2009. Thirty seven caeses 
were excluded due to primary access failure and loss of follow-up. One group of 92 autogenous arterioveous fistu-
las and the other group of 37 arteriovenous prosthetic grafts were evaluated retrospectively. Primary and secondary 
patency rates were estimated using the Kaplan-Meier method. Results: The primary patency rate (84%, 67%, 51% 
vs. 51%, 22%, 9% at 1, 3, 5 year; p=0.0000) and secondary patency rate (96%, 88%, 68% vs. 88%, 65%, 16% 
at 1. 3, 5 year; p=0.0009) were better in autogenous fistula group than prosthetic graft group. Interventions to 
maintain secondary patency were required in 23% of the autogenous fistula group (average 0.06 proce-
dures/patient/year) and 65% of prosthetic graft group (average 0.21 procedures/patient/year). So the autogenous fis-
tula group had fewer intervention rate than prosthetic graft group (p=0.01) The risk factor of primary patency was 
diabetus combined with ischemic heart disease and the secondary patency’s risk factor was age. Conclusion: 
Autogenous arteriovenous fistulas showed better performance compared to prosthetic grafts in terms of primary & 
secondary patency and incidence of interventions. 
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INTRODUCTION
Maintaining  a  functionally  good  arteriovenous  fistula  is 
very  important  in  chronic  renal  failure  patients  for  effective 
hemodialysis  treatment.  However,  complications  related  with 
arteriovenous  fistula  are  the  most  crucial  cause  to  morbidity 
rate of patients treated with hemodialysis, which takes a large 
part  in  treatment  cost.  There  are  three  types  of  hemodialysis 
access:  autogenous  arteriovenous  fistula,  arteriovenus  pros-
thetic  graft,  and  central  venous c a t h e t e r .  A m o n g  t h e s e  t y p e s ,  
mature  autogenous  arteriovenous  fistula  is  known  to  be  the 
best  hemodialysis method  with promising  good  long-term  pa-Duk-Sil Kim, et al
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Table 1. Vascular access procedures
Autogenous  AVF Prosthetic  AVG
Radio-cephalic  direct  wrist 78
Radio-cephalic  direct  cubital 6
Brachial-cephalic  upper  arm  direct 28
Brachial-basilic  upper  arm  transposition 5
Total  cases  166  (100%) 119  (71%)
          Brachial-antecubital  forearm  loop 44
          Brachial-axillary  straight 5
49  (29%)
Primary  access  failure  rate  (7.8%):  AVF  10  (8.4%),  AVG  3  (6.1%).  AVF=Arteriovenous  fistula;  AVG=Arteriovenous  graft.
tency  rate  and  low  morbidity  rate  [1].
Autogenous arteriovenous fistula has its own weakness that 
it  has  a  greater  rate  in  failure  to  maturity  when  compared 
with  prosthetic  graft.  However,  when  autogenous  arterio-
venous  fistula  is  successfully  used  in  hemodialysis,  it  shows 
significantly  lower  occurrence  of  revision  for  long-term  pa-
tency  than  prosthetic  graft.  According  to  National  Kidney 
Foundation-kidney  disease  outcomes  Quality  Initiative  guide-
lines (NFK/KDOQI), using an autogenous arteriovenous fistu-
la  such  as  radiocephalic  fistula  or  brachiocephalic  fistula  is 
recommended.  However,  when  the  patient  is  female,  older, 
obese,  diabetic,  or  has  peripheral  vascular  disease,  usage  of 
autogenous  arteriovenous  fistula  is  known  to  be  relatively 
low. Also, prosthetic graft can be an appropriate alternative in 
cases  where  autogenous  arteriovenous  fistula  has  failed  or 
could  not  be  used  [1-3]. 
Authors  of  this  research  retrospectively  observed  patients 
gone  through  arteriovenous  fistula  operations.  Authors  ana-
lyzed  the  differences  in  primary  and  secondary  patency  rates 
of  autogenous  arteriovenous  fistula  group  and  arteriovenous 
prosthetic  graft  group.  Risk  factors  affecting  the  patency  rate 
along with revision method and frequency to maintain secon-
dary  patency  were  analyzed.
MATERIAL AND METHODS
Patients  gone  through  autogenous  arteriovenous  fistula  or 
arteriovenous prosthetic graft operations from December, 2002 
to  November,  2009  were  considered  as  the  subject  group. 
The  patency  rates  up  to  March  31st,  2010  were  retro-
spectively researched. Total number of operations in 153 sub-
ject  patients  was  166.  117  cases  were  autogenous  arterio-
venous  fistula  and  49  cases  were  arteriovenous  prosthetic 
graft  with  polytetrafluorethylene  (PTFE)  material  (Table  1). 
Among  these patients,  129  cases were set as  research  subject 
excluding  37  cases  with  primary  access  failure,  postoperative 
early  death,  kidney  replacement,  peritoneal  dialysis,  and  loss 
of follow-up observation. There were frequency differences of 
diabetes,  hypertension,  and  ischemic  heart  disease  between 
two  groups  (Table  2).
Clinic’s medical record was referred in patients with possi-
ble clinic follow-up observation and phone interview with the 
patient or dialysis clinic was done for patients gone to differ-
ent  clinics  for  hemodialysis.
Primary and secondary patency difference in autogenous ar-
teriovenous  fistula  or  arteriovenous  prosthetic  graft  was  ob-
served  along  with  factors  affecting  patency  such  as  primary 
diseases causing chronic renal failure, age, sex, and associated 
diseases.  In  addition,  revision  method  and  frequency  differ-
ence in cases where autogenous arteriovenous fistula and arte-
riovenous  prosthetic  graft  failed  functionally  were  investi-
gated.
Primary  patency  was  defined  as  the  time  period  from  for-
mation  of  arteriovenous  fistula  to  first  revision  due  to  mal-
function  of  arteriovenous  fistula  such  as  stricture  or 
thrombosis.  Secondary  or  cumulative  patency  was  defined  as 
the  time  period  from  formation  of  arteriovenous  fistula  to 
complete  failure  to  hemodialysis  with  the  corresponding  arte-
riovenous fistula disregarding the number of revisions. In cas-
es  where  the  patient  deceased  or  the  follow-up  was  lost  be-
fore  primary  or  secondary  patency  were  considered  as  cen-
sored data. Primary access failure was defined as cases where 
hemodialysis  could  not  be  done  properly  due  to  early  ob-
struction  of  arteriovenous  fistula  or  immuturity.  In  this  re-
search,  13  cases  (7.8%)  had  primary  access  failure  and  were 
excluded  from  patency  analysis  subject  group.Clinical Analysis of Vascular Access: Comparison of Autogenous Fistula & Graft
− 27  −
Table 2. Patients characteristics 
A V F  ( 9 2  c a s e s ) A V G  ( 3 7  c a s e s ) p - v a l u e
Age  (Y)
Men  (%)
Primary  disease  (DM/non  DM)
DM
GN
PCKD
Other  &  unknown
Comobidity
HTN
CVA
IHD
PAD
CHF
55.4±13.7
57  (62.0%)
42  (45.7%)
17  (18.5%)
1  (1.1%)
32  (34.8%)
63  (68.5%)
13  (14.1%)
7  (7.6%)
4  (4.4%)
5  (5.4%)
59.8±10.4
16  (43.2%)
31  (83.8%)
 5  ( 1 3 . 5 % )
1  (2.7%)
1  (2.7%)
16  (43.2%)
 8  ( 2 1 . 6 % )
 8  ( 2 1 . 6 % )
1  (2.7%)
2  (5.4%)
 0 . 0 5 3
 0 . 0 5 2
0.00
0.49
0.51
0.00
0.01
0.30
0.03
0.65
1.0
DM=Diabetes  mellitus;  GN=Glomerulonephritis;  PCKD=Poly  cystic  kidney  disease;  HTN=Hypertensiom;  CVA=Cerebrovascular  acci-
dent;  IHD=Ischemic  heart  disease;  PAD=Peripheral  arterial  disease;  CHF=Congestive  heart  failure;  AVF=Arteriovenous  fistula; 
AVG=Arteriovenous  graft.
Table 3. Primary patency rates of hemodialysis access
                       P a t e n c y  r a r e s
Access  type 1  year  (%) 2  year  (%) 3  year  (%) 5  year  (%)
Autogenous  AVF
Prosthetic  AVG
84  (CI  75∼90)
51  (CI  34∼66)
72  (CI  61∼81)
28  (CI  15∼44)
6 7  ( C I  5 5 ∼76)
2 2  ( C I  1 0 ∼37)
51  (CI  38∼63)
9  (CI  2∼23)
AVF=Arteriovenous  fistula;  AVG=Arteriovenous  graft.
SPSS  (PASW)  statistics  17.0.2  was  used  for  statistical 
analysis.  T-test,  chi-square  test,  and  correlation  analysis  were 
used  for  variable  comparison  within  two  groups.  Survival 
analysis  such  as  Kaplan-Meier  survival  curve,  log  rank  test, 
and  Cox  proportional  hazard  model  were  used  for  primary 
and  secondary  patency  rates.  Cox  proportional  hazard  model 
was  composed  of  factors  that  showed  significant  relationship 
with independent or result variable in univariate analysis. The 
factors  were  age,  diabetes,  hypertension,  and  ischemic  heart 
disease.  Statistically  significant  level  was  considered  as  p
＜0.05.
RESULTS
1) Primary patency rate, patency period, and related 
factors
Primary  patency  rates  in  1,  2,  3,  and  5-year  period  were 
84%, 72%, 67%, and 51% with autogenous arteriovenous fis-
tula  and  51%,  28%,  22%,  and  9%  with  prosthetic  arterio-
venous  graft  (Table  3).  This  shows  that  autogenous  arterio-
venous fistula reveals better primary patency rate than that of 
prosthetic  arteriovenous  graft  with  statistically  significant  re-
s u l t s  ( p = 0 . 0 0 0 0 )  ( F i g .  1 ) .  A v e r a g e  p r i m a r y  p a t e n c y  p e r i o d s  
were  936.7±663.9  days  for  autogenous  arteriovenous  fistula 
and  500.9±453.1  days  for  prosthetic  graft  (p=0.0000).  It  also 
shows  statistically  significant  results.
Risk factors related with patency rate such as diabetes, hy-
pertension,  and  ischemic  heart  disease  that  showed  difference 
in  two  groups  were  analyzed  with  Cox  proportional  Hazard 
model.  Diabetes  occurred  more  frequently  in  prosthetic  arte-
riovenous  graft,  but  did  not  affect  patency  rate.  However, 
considering  ischemic  heart  disease  directly  related  with  dia-
betes,  diabetes  followed  by  ischemic  heart  disease  acted  as  a 
risk  factor  by  affecting  primary  patency  rate  (p=0.040).Duk-Sil Kim, et al
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Table 4. Secondary patency rates of hemodialysis access
                      P a t e n c y  r a r e s
Access  type 1  year  (%) 2  year  (%) 3  year  (%) 5  year  (%)
Autogenous  AVF
Prosthetic  AVG
96  (CI  89∼99)
88  (CI  72∼95)
91  (CI  82∼95)
73  (CI  54∼85)
8 8  ( C I  7 8 ∼93)
6 5  ( C I  4 5 ∼79)
68  (CI  53∼80)
16  (CI  1∼47)
AVF=Arteriovenous  fistula;  AVG=Arteriovenous  graft.
Fig. 1. Primary patency rates of AVF & AVG: Kaplan-Meier sur-
vival estimates. AVF=Arteriovenous fistula; AVG=Arteriovenous graft.
Fig. 2. Secondary patency rates of AVF & AVG: Kaplan-Meier 
survival estimates. AVF=Arteriovenous fistula; AVG=Arteriovenous 
graft.
2) Secondary patency rate, patency period, and related 
factors
Secondary patency rates in 1, 2, 3, and 5-year period were 
96%, 91%, 88%, and 68% with autogenous arteriovenous fis-
tula  and  88%,  73%,  65%,  and  16%  with  prosthetic  arterio-
venous  graft  (Table  4).  This  implies  that  autogenous  arterio-
venous fistula shows statistically better secondary patency rate 
(p=0.0009)  (Fig.  2).  Average  secondary  patency  period  was 
1,079.3±645.7  days  for  autogenous  arteriovenous  fistula  and 
880.6±464.9  days  for  prosthetic  graft.  Autogenous  arterio-
venous fistula showed better results, but it was not significant 
statistically  (p=0.0541). 
    Cox  proportional  Hazard  model  was  executed  to  analyze 
risk  factors  related  to  patency  rate  such  as  age,  diabetes,  hy-
pertension,  and  ischemic  heart  disease.  Significant  risk  factor 
affecting  secondary  patency  rate  was  age.  Occurrence  of  dia-
betes  and  ischemic  heart  disease  was  more  frequent  in  pros-
thetic  graft  than  autogenous  arteriovenous  fistula,  but  it  did 
not  affect  secondary  patency  rate.
Endovascular or surgical revisions for secondary patency in 
autogenous  arteriovenous  fistula  were  executed  in  21  out  of 
92  cases  (23%)  with  a  total  of  40  repairs  (0.06  revision  per 
patient per year). On the other hand, endovascular or surgical 
revisions  for  secondary  patency  in  prosthetic  graft  were  exe-
cuted  in  24  out  of  27  cases  (65%)  with  a  total  of  54  repairs 
(0.21  revision  per  patient  per  year).  These  results  show  that 
revision  occurrence  was  significantly  lower  in  autogeneus  ar-
teriovenous  fistula  than  prosthetic  graft  (p=0.01).
For  location  of  autogenous  arteriovenous  fistula's  stenosis 
or  occlusion,  draining  vein  had  the  greatest  occurrence  with 
25  cases  (63%).  Nine  cases  occurred  at  proximal  anastomic 
site  3∼4  cm  from  arteriovenous  anastomose,  one  case  oc-
curred at central vein, one case occurred at inflow artery, and 
four cases at other locations. For methods of revision, balloon 
angioplasty  was  used  in  15  cases,  thrombectomy  with  graft 
interposition  was  used  in  8  cases,  thrombectomy  with  patch 
angioplasty  was  used  in  5  cases,  graft  interposition  was  used 
in  5  cases,  simple  thrombectomy  was  used  in  4  cases,  and Clinical Analysis of Vascular Access: Comparison of Autogenous Fistula & Graft
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thrombectomy  with  balloon  angioplasty  was  used  in  3  cases.
Complications  and  causes  of  stricture  and  thrombosis  in 
prosthetic  graft  varied.  20  cases  had  mild  stenosis  at  venous 
anastomosis  or  unknown  cause.  After  thrombectomy,  stilet 
with  diameter  of  3.5  mm  easily  passed  through  venous  anas-
tomosis  site  and  thrill  was  palpated  on  the  skin.  Among  dis-
covered  causes,  venous  anastomosis  site  stenosis  was  the 
most  frequent  with  19  cases,  venous  anastomosis  site  and 
draining  vein  occurred  in  10  cases,  false  aneurysm  occurred 
in 2 cases, graft infection occurred in 2 cases, and central ve-
nous occlusion occurred in 1 case. In types of revision meth-
od, simple thrombectomy was done in 20 case, thrombectomy 
with  jump  graft  was  done  in  17  cases,  thrombectomy  with 
balloon  angioplasty  was  done  in  9  cases,  thrombectomy  with 
patch  angioplasty  was  done  in  2  cases,  and  resection  with 
graft  interposition  was  done  in  4  cases.
DISCUSSION
According  to  Dialysis  Outcomes  and  Practice  Patterns 
Study (DOPPS) (studying international trends of hemodialysis 
access  usage  in  chronic  renal  failure  patients),  frequency  of 
autogenous arteriovenous fistula usage differs from country to 
country.  According  to  the  data  after  2005,  Japan,  Italy, 
Germany,  France,  Spain,  and  England  showed  67∼91%  of 
autogenous  arteriovenous  fistula  usage  rate  where  as  United 
Stated  showed  the  lowest  rate  of  47%.  The  differency  of  au-
togenous  arteriovenous  fistula  usage  rate  in  each  countries 
can  be  assumed  as  the  fact  that  occurrence  rates  of  diabetes, 
angina  pectoris, and peripheral vascular disease are  greater in 
patients from the United States than in patients from Japan or 
other  Europe  countries.  However,  the  fact  that  frequency  of 
autogenous  arteriovenous  fistula  usage  in  patients  from  the 
United  States  is  lower  than  patients  from  Europe  even  after 
modifying  associated  other  diseases  can  be  implied  as  the 
high  preference  to  prosthetic  graft  among  surgeons  in  US 
[1,4].  In  author’s  study,  autogenous  arteriovenous  fistula  us-
age  rate  was  70%  coinciding  the  international  clinical 
guideline.
There are no opposition on the fact that ideal hemodialysis 
access  should  be  durable  and  has  low  risk  of  infection  and 
frequency  for  revision  operation  to  maintain  patency.  It  is 
true  that  there  are  a  few  researches  with  analytical  results 
saying  there  is  no  difference  in  patency  between  autogenous 
arteriovenous  fistula  and  prosthetic  arteriovenous  graft  [5,6]. 
However,  according  to  numorous  research  results,  autogenous 
arteriovenous fistula showed better results than prosthetic arte-
riovenous  graft  [7-10].    Author’s  study  also  showed  that    au-
togenous arteriovenous fistula gives better results in frequency 
of  revision  operation  and  primary  &  secondary  patency  rate.
According to a large research result from the United States, 
in 2-year patency rate, primary patency rate of autogenous ar-
teriovenous  fistula  showed  better  reselts  with  39.8%  when 
compared  with  that  of  prosthetic  graft  with  24.6%.  However, 
secondary patency rate difference between autogenous arterio-
venous  fistula  and  prosthetic  graft  was  not  significant  with 
64.3%  and  59.5%.  Also,  autogenous  arteriovenous  fistula  us-
ing  venous  transposition  showed  similar  secondary  patency 
rate  when  compared  with  simple  autogenous  arteriovenous 
fistula. It was also shown that female, elders, or patients with 
previous  arteriovenous  fistula  fa i l u r e  h a d  b e n e f i t s  u s i n g  t h e  
venous  transposition  fistula  [11]. 
Woo  et  al.  [8]  showed  in  his  research  about  comparison 
between  autogenous  arteriovenous  fistula  using  venous  trans-
position and linear shaped prosthetic graft that autogenous fis-
tula  was  better  than  prosthetic  graft  in  both  primary(48%  vs. 
14%) and  secondary(57% vs. 19%)  patency rate at 5-year. In 
addition,  revision  frequency  for  secondary  patency  was  sig-
nificantly  lower  in  autogenous  arteriovenous  fistula.  They  in-
sisted  that  autogenous  arteriovenous  fistula  should  be  primar-
ily  made  when  anatomical  conditions  satisfy  with  adequate 
arterial inflow bloodstream and large diameter of vein greater 
than  2.5  mm.
Although beginning hemodialysis with a mature autogenous 
arteriovenous  fistula  is  ideal  in  all  patients  without  using  the 
catheter,  there  are  numerous  obstacles  to  overcome.  The  pa-
tients must be refered to nephrologist before terminal stage of 
renal failure, arteriovenous  fistula operation  must be executed 
beforehand  for  maturity,  and  a  trained  dialysis  nurse  must 
successfully  execute  needdling.  However, if one of the  above 
conditions is not met, using the catheter is inevitable. In case 
of  the  United  States,  approximately  60∼65%  of  the  patients 
begin  hemodialysis  with  the  catheter  [2].
According to KDOQI clinical guideline, autogenous arterio-Duk-Sil Kim, et al
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venous  fistula  must  be  made  approximately  6  months  before 
the estimated hemodialysis treatment. This is because periodic 
evaluation  for  maturation  and  additional  revisions  before  be-
ginning  of  hemodialysis  are  necessary.  Average  maturation 
term  of  autogenous  arteriovenous  fistula  is  2∼4  months  and 
that  of  prosthetic  arteriovenous  graft  is  approximately  3∼6 
weeks  [3].
According  to  KDOQI  (Kidney  Disease  Outcomes  Quality 
Initiative) clinical guideline revised in 2006, greater than 65% 
of  the  hemodialysis  patients  are  suggested  to  use  autogenous 
arteriovenous  fistula.  In  order  to  increase  usage  frequency  of 
autogenous arteriovenous fistula and achieve successful hemo-
dialysis  access,  preoperative  thorough  history  investigation, 
physical  examination,  and  ultrasonic  vessel  mapping  are 
necessary.  Using  autogenous  vessel  might  be  challenging,  es-
pecially  in  patients  who  are  diabetic,  old,  female,  or  has  pe-
ripheral vascular disease, or severe heart failure. If an arterial 
radius  is  at  least  2  mm  through  preoperative  doppler  ultra-
sonic  examination  and  shows  positive  reactive  hyperemia  re-
sponse(changes  in  arterial  waveform  with  increased  blood 
flow  after  holding  fist  for  30  seconds),  the  artery  is  appro-
priate  for  autogenous  arteriovenous  fistula.  Vein  mapping  us-
ing ultrasound can help deciding the operable site by evaluat-
ing the diameter, patency, continuity, and distensibility [3-12].
Silvia  et  al.  [13]  reported  that  non-invasive  preoperative 
test  could  increase  the  use  of  autogenous  arteriovenous  fistu-
la,  reduce  postoperative  early  failure,  and  improve  secondary 
patency  rate.  Non-invasive  tests  were  both  arm  arterial  seg-
mental  pressure  measurement  and  Doppler  ultrasound  exami-
nations for  arteries & veins. As a  baseline for  surgery, upper 
arm  blood  pressure  in  each  side  should  not  be  different,  the 
arterial  diameter  must  be  greater  than  2  mm,  palmer  arch 
must be patent, and the venous diameter must be greater than 
2.5  mm  for  autogenous  fistula  &  4  mm  for  prosthetic  graft. 
Also,  there  should  be  no  narrowed  or  blocked  segment,  con-
tinuity with deep vein must be maintained, and no stricture or 
occlusion  in  ipsilateral  central  vein.
Jo et al. [14] reported in his research that there are no dif-
ference  in  patency  rate  between autogenous arteriovenous  fis-
tula  and  prosthetic  arteriovenous  graft.  However,  autogenous 
arteriovenous  fistula  showed  better  long-term  results  both  in 
primary and secondary patency rate in this research. In analy-
sis  of  risk  factors  affecting  patency  rate,  diabetes  appeared 
more  frequently  in  prosthetic  arteriovenous  graft.  However, 
diabetes alone was not a risk factor of primary and secondary 
patency  rate.  In  cases  where  diabetes  was  followed  by  ische-
mic  heart  disease,  it  appeared  as  a  significant  risk  factor  in 
primary  patency  rate.  Age  appeared  as  a  significant  risk  fac-
tor  in  secondary  patency  rate.
CONCLUSION
In  this  research,  autogenous  arteriovenous  fistula  showed 
better  results  than  prosthetic  arteriovenous  graft  in  both  pri-
mary  and  secondary  patency  rate.  It  also  showed  lower  fre-
quency  in  revisions  due  to  complications  such  as  stricture  or 
thrombosis.  In  order  to  increase  the  use  of  autogenous  arte-
riovenous  fistula,  artriovenous  fistula  surgery  must  be  exe-
cuted  before  estimated  hemodialysis  start  and  appropriate  lo-
cation of vessel must be found through thorough preoperative 
tests  such  as  ultrasound  vessel  mapping.  Risk  factor  for  pri-
mary patency rate is the case having both diabetes and ische-
mic  heart  disease.  In  cases  like  this  where  cardiovascular 
complications  might  follow,  more  thorough  preoperative  tests 
must  be  performed  and  periodical  assessment  for  arterio-
venous  fistula  must  be  done  after  surgery  to  prevent  compli-
cations  such  as  stricture.  In  author’s  case,  prosthetic  arterio-
venous  graft  patency  rate  was  relatively  too  low.  Therefore, 
effort  to  improve  patency  rate  of  prosthetic  arteriovenous 
graft  is  necessary.
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